Organovo Holdings Inc
NASDAQ:ONVO
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Organovo Holdings Inc
Revenue
Organovo Holdings Inc
Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Organovo Holdings Inc
NASDAQ:ONVO
|
Revenue
$122k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-47%
|
CAGR 10-Years
-12%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Revenue
$61.2B
|
CAGR 3-Years
2%
|
CAGR 5-Years
6%
|
CAGR 10-Years
10%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Revenue
$29.4B
|
CAGR 3-Years
3%
|
CAGR 5-Years
4%
|
CAGR 10-Years
-1%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Revenue
$36.8B
|
CAGR 3-Years
12%
|
CAGR 5-Years
8%
|
CAGR 10-Years
5%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Revenue
$12B
|
CAGR 3-Years
10%
|
CAGR 5-Years
14%
|
CAGR 10-Years
28%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Revenue
$14.3B
|
CAGR 3-Years
6%
|
CAGR 5-Years
11%
|
CAGR 10-Years
13%
|
|
Organovo Holdings Inc
Glance View
Organovo Holdings, Inc. engages in the development of bioprinted human tissues that emulate human biology and disease. The company is headquartered in San Diego, California and currently employs 7 full-time employees. The company went IPO on 2013-08-02. The firm is focused on building high fidelity, three-dimensional (3D) tissues that recapitulate key aspects of human disease. The firm is targeting the intestine and has ongoing 3D tissue developments in Ulcerative colitis (UC) and Crohn's disease (CD). The firm uses its platform technology to build functional 3D human tissues that mimic key aspects of native human tissue composition, architecture, function and disease. Its NovoGen Bioprinters are automated devices that enable the fabrication of 3D living tissues comprised of mammalian cells. NovoGen Bioprinters can dispense pure hydrogel formulations and also serve as important components of company's tissue prototyping and manufacturing platform. The firm also intends to use its bioprinting platform as well as 3D technologies to treat its target diseases.
See Also
What is Organovo Holdings Inc's Revenue?
Revenue
122k
USD
Based on the financial report for Dec 31, 2024, Organovo Holdings Inc's Revenue amounts to 122k USD.
What is Organovo Holdings Inc's Revenue growth rate?
Revenue CAGR 10Y
-12%
Over the last year, the Revenue growth was -50%.
